Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes

30 May 2011

Abstract excerpt

Azacitidine, an inhibitor of DNA methyltransferase, is reported to have antileukemic efficacy and is approved for the treatment of myelodysplastic syndromes in Western countries. We have conducted a Phase I/II study of azacitidine in Japanese patients with myelodysplastic syndromes to evaluate its pharmacokinetics, efficacy, and safety. In all, 53 patients received 75 mg/m(2) azacitidine subcutaneously or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Hematopoietic Stem Cell Transplantation
Share to Pneumocystis jirovecii pneumonia detection and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21624006
DOI: 10.1111/j.1349-7006.2011.01993.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromesPMID 21624006Read ↗

Demethylating Agents in the Treatment of CancerSemantic proximity Read ↗

DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studiesSemantic proximity Read ↗

New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic SyndromeSemantic proximity Read ↗

DNA Methyltransferase Inhibitors and their Therapeutic PotentialSemantic proximity Read ↗

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromesSemantic proximity Read ↗

Review: Recent Clinical Trials in Epigenetic TherapySemantic proximity Read ↗

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.Semantic proximity Read ↗

[Hypomethylating agents for the treatment of myelodysplastic syndromes].Semantic proximity Read ↗

Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating AgentsSemantic proximity Read ↗

Azacitidine regulates DNA methylation of GADD45γ in myelodysplastic syndromesSemantic proximity Read ↗

Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndromeSemantic proximity Read ↗

Azacitidine differentially affects CD4pos T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.